Edition:
United States

Repros Therapeutics Inc (RPRX.OQ)

RPRX.OQ on NASDAQ Stock Exchange Capital Market

0.66USD
3:59pm EST
Change (% chg)

$0.19 (+41.45%)
Prev Close
$0.47
Open
$0.66
Day's High
$0.68
Day's Low
$0.66
Volume
2,570,683
Avg. Vol
189,355
52-wk High
$1.55
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Repros Therapeutics Announces Acquisition By Allergan
6:30am EST 

Dec 12 (Reuters) - Repros Therapeutics Inc ::REPROS THERAPEUTICS INC.® ANNOUNCES ACQUISITION BY ALLERGAN PLC.REPROS THERAPEUTICS INC - DEAL FOR $0.67 PER SHARE.REPROS THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT UNDER WHICH ALLERGAN PLC, THROUGH A SUBSIDIARY, WILL ACQUIRE REPROS.REPROS THERAPEUTICS INC - COMPANY'S BOARD OF DIRECTORS HAS UNANIMOUSLY APPROVED TRANSACTION.  Full Article

Repros Therapeutics Q3 loss per share $0.04
Monday, 13 Nov 2017 08:45am EST 

Nov 13 (Reuters) - Repros Therapeutics Inc -:Repros Therapeutics Inc.® reports third quarter 2017 financial results.Q3 loss per share $0.04.Repros Therapeutics Inc - ‍cash and cash equivalents of approximately $1.8 million as of September 30, 2017 as compared to $8.7 million as of December 31, 2016​.  Full Article

Rosalind Advisors reports 5.7 pct stake in Repros Therapeutics
Monday, 24 Jul 2017 05:09pm EDT 

July 24 (Reuters) - Repros Therapeutics Inc ::Rosalind Advisors Inc reports 5.7 percent passive stake in Repros Therapeutics Inc as of July 20 - SEC filing.  Full Article

Repros Therapeutics says files for potential stock shelf offering - SEC filing‍​
Monday, 24 Jul 2017 03:30pm EDT 

July 24 (Reuters) - Repros Therapeutics Inc ::Repros Therapeutics Inc files for potential stock shelf offering of up to 4.5 million shares - SEC filing‍​.  Full Article

Repros Therapeutics ‍expects to receive European patent ‍​
Monday, 17 Jul 2017 06:30am EDT 

July 17 (Reuters) - Repros Therapeutics Inc ::Repros Therapeutics Inc - ‍expects to receive European patent that relates to selective progesterone modulators​.Repros Therapeutics Inc - ‍repros assessing uterine fibroid and endometriosis development program with vaginal drug delivery treatment​.Repros - ‍FDA indicated that company will be required to compile a large pre-approval safety data base to support future development of proellex program​.Repros Therapeutics Inc - proellex development program will remain on partial clinical hold by FDA​.  Full Article

Repros Therapeutics Q1 loss per share $0.22
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Repros Therapeutics Inc :Repros Therapeutics Inc. reports first quarter 2017 financial results.Q1 loss per share $0.22.  Full Article

Repros names Larry Dillaha M.D. its permanent president and CEO
Monday, 10 Apr 2017 09:18am EDT 

Repros Therapeutics Inc - : Repros names Larry Dillaha, M.D., its permanent president and ceo . Dillaha has also been named to board, filling an existing vacancy . Dillaha was previously chief executive officer of Cavtherx, an inception stage biotechnology company .Dillaha has been serving as president, chief executive officer on an interim basis since February 1, 2017.  Full Article

Repros Therapeutics meets with FDA to discuss Proellex in treatment of uterine fibroids
Monday, 10 Apr 2017 09:15am EDT 

Repros Therapeutics Inc : Company holds meeting with FDA to discuss oral Proellex® in the treatment of uterine fibroids . Before meeting, was notified meeting would be Type C/guidance meeting, rather than Type B/end of Phase 2 meeting as previously expected . Company intends to announce further information following receipt of additional guidance from FDA on oral Proellex . Company expects to submit additional information and a proposed clinical protocol within a month on oral Proellex . FDA confirmed Proellex to continue on current partial clinical hold . Proellex to continue on partial clinical hold while FDA consult's with its liver experts regarding previously disclosed effects on liver .FDA agreed to accept additional information from co, its panel of liver experts for consideration by FDA's internal advisory liver team.  Full Article

Repros Therapeutics Inc reports • Q4 loss per share $0.16
Friday, 31 Mar 2017 09:15am EDT 

Repros Therapeutics Inc : Repros Therapeutics Inc reports fourth quarter and year end 2016 financial results .Q4 loss per share $0.16.  Full Article

Repros announces new CEO
Thursday, 2 Feb 2017 09:15am EST 

Repros Therapeutics Inc : Repros announces new CEO . Says ceo and president Joseph S. Podolski resigned .Larry Dillaha was appointed interim president and chief executive officer of company, effective immediately.  Full Article